jetcityimage / iStockphoto.com
GSK has revealed plans to cut back on research and development (R&D), while Eli Lilly announced a plan to focus its R&D resources on oncology.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, Eli Lilly, research & development, R&D, innovation, cancer, drugs, pharmaceuticals, drug development